Lynch syndrome: Clinical, pathological, and genetic insights

Langenbeck's Archives of Surgery

Volumn 397, Issue 4, 2012, Pages 513-525

  Schneider, Ralph ^a   Schneider, Claudia ^b   Kloor, Matthias ^c   Fürst, Alois ^d   Möslein, Gabriela ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b St Josef Hospital   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d CARITAS KRANKENHAUS ST JOSEF   (Germany)

Author keywords

Genetic testing; Immunohistochemistry; Lynch syndrome; Mismatch repair genes; MSI analysis; Prophylactic surgery

Indexed keywords

ACETYLSALICYLIC ACID; CANCER VACCINE; DNA GLYCOSYLASE MUTY; FRAMESHIFT PEPTIDE ANTIGEN; PLACEBO; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COLORECTAL TUMOR; DNA METHYLATION; DRUG MEGADOSE; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR GENETICS; NUCLEAR FAMILY; ONSET AGE; PATIENT IDENTIFICATION; POLYPOSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TREATMENT INDICATION;

ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GUIDELINE ADHERENCE; HETEROZYGOTE DETECTION; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PEDIGREE; QUALITY OF LIFE;

EID: 84863986590     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-012-0918-8     Document Type: Review

References (127)

1. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488 (Pubitemid 40458328)
2. Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85 (Pubitemid 30451850)
3. Jasperson KW, Tuohy TM, Neklason DW, Burt RW (2010) Hereditary and familial colon cancer. Gastroenterology 138:2044-2058
4. Johns LE, Houlston RS (2001) A systematic review and metaanalysis of familial colorectal cancer risk. Am J Gastroenterol 96:2992-3003 (Pubitemid 32959544)
5. Goodenberger M, Lindor NM (2011) Lynch syndrome and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol 45:488-500
6. Vasen HF, van der Meulen-de Jong AE, de Vos Tot Nederveen Cappel WH, Oliveira J (2009) Familial colorectal cancer risk: ESMO clinical recommendations. Ann Oncol 20(Suppl 4):51-53
7. Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481-1487 (Pubitemid 28226275)
8. Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783-5788
9. Cunningham JM, Kim CY, Christensen ER et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780-790 (Pubitemid 32868523)
10. Cantor D (2006) The frustrations of families: Henry Lynch, heredity, and cancer control, 1962-1975. Med Hist 50:279-302 (Pubitemid 44882944)
11. Lynch HT, Smyrk T, Lynch JF (1998) Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from pedigree anecdote to molecular genetic confirmation. Oncology 55:103-108 (Pubitemid 28052253)
12. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ (1966) Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 117:206-212
13. Lynch HT, Krush AJ (1971) Cancer family "G" revisited: 1895-1970. Cancer 27:1505-1511
14. Warthin AS (1913) Hereditary with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med 117:206-212, Ref Type: Journal (Full)
15. Lynch HT, Drouhard TJ, Schuelke GS, Biscone KA, Lynch JF, Danes BS (1985) Hereditary nonpolyposis colorectal cancer in a Navajo Indian family. Cancer Genet Cytogenet 15:209-213 (Pubitemid 15140843)
16. Boland CR, Troncale FJ (1984) Familial colonic cancer without antecedent polyposis. Ann Intern Med 100:700-701 (Pubitemid 14143948)
17. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456 (Pubitemid 29258894)
18. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268 (Pubitemid 38256271)
19. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1-18
20. Moslein G (2008) Hereditary colorectal cancer. Chirurg 79:1038-1046
21. Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979-1985 (Pubitemid 40570891)
22. Jass JR (2006) Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol 12:4943-4950 (Pubitemid 44323261)
23. Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29:849-853 (Pubitemid 17208885)
24. Bellizzi AM, Frankel WL (2009) Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 16:405-417
25. Stoffel E, Mukherjee B, Raymond VM et al (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621-1627
26. Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851-1860
27. Weissman SM, Bellcross C, Bittner CC et al (2011) Genetic counseling considerations in the evaluation of families for Lynch syndrome-a review. J Genet Couns 20:5-19
28. Hampel H, Frankel W, Panescu J et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810-7817 (Pubitemid 44289242)
29. Vasen HF, Watson P, Mecklin JP et al (1994) The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14:1675-1678 (Pubitemid 24357004)
30. Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415-421 (Pubitemid 41096629)
31. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP (1996) Better survival rates in patients withMLH1-associated hereditary colorectal cancer. Gastroenterology 110:682-687 (Pubitemid 26071836)
32. Albano WA, Recabaren JA, Lynch HT et al (1982) Natural history of hereditary cancer of the breast and colon. Cancer 50:360-363 (Pubitemid 12089401)
33. Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT (1994) Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res 14:1631-1634 (Pubitemid 24356996)
34. Vasen HF, Mecklin JP, Watson P et al (1993) Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 36:1-4 (Pubitemid 23019435)
35. Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF, Bardawil WA (1977) Role of heredity in multiple primary cancer. Cancer 40:1849-1854 (Pubitemid 8216956)
36. Mecklin JP, Jarvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29:160-164 (Pubitemid 16124067)
37. Lynch HT, de la Chapelle A (1999) Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 36:801-818 (Pubitemid 29520569)
38. Goecke T, Schulmann K, Engel C et al (2006) Genotypephenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 24:4285-4292 (Pubitemid 46630786)
39. Ponti G, Losi L, Pedroni M et al (2006) Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 126:2302-2307 (Pubitemid 44413178)
40. South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A (2008) The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 100:277-281 (Pubitemid 351480531)
41. Ollila S, Fitzpatrick R, Sarantaus L et al (2006) The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC. Int J Oncol 28:149-153
42. Lynch HT, Fusaro RM, Roberts L, Voorhees GJ, Lynch JF (1985) Muir-Torre syndrome in several members of a family with a variant of the cancer family syndrome. Br J Dermatol 113:295-301 (Pubitemid 15246604)
43. Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758-1762
44. Kievit W, de Bruin JH, Adang EM et al (2004) Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 65:308-316 (Pubitemid 38443554)
45. Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J (2000) Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 36:49-54 (Pubitemid 30035343)
46. Pinol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients withhereditary nonpolyposis colorectal cancer. JAMA 293:1986-1994 (Pubitemid 40570892)
47. Salovaara R, Loukola A, Kristo P et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193-2200 (Pubitemid 30350210)
48. Julie C, Tresallet C, Brouquet A et al (2008) Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelinesbased approach versus molecular screening. Am J Gastroenterol 103:2825-2835
49. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11:42-65
50. Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507-1517 (Pubitemid 44465515)
51. Church J, McGannon E (2000) Family history of colorectal cancer: how often and how accurately is it recorded? Dis Colon Rectum 43:1540-1544
52. Katballe N, Juul S, Christensen M, Orntoft TF, Wikman FP, Laurberg S (2001) Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. Br J Surg 88:1228-1233 (Pubitemid 34015608)
53. Sijmons RH, Boonstra AE, Reefhuis J et al (2000) Accuracy of family history of cancer: clinical genetic implications. Eur J Hum Genet 8:181-186 (Pubitemid 30189861)
54. van Lier MG, Wagner A, van Leerdam ME et al (2010) A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med 14:181-197
55. Jenkins MA, Hayashi S, O'Shea AM et al (2007) Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133:48-56 (Pubitemid 47039240)
56. Young J, Simms LA, Biden KG et al (2001) Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 159:2107-2116 (Pubitemid 33104265)
57. Greenson JK, Bonner JD, Ben-Yzhak O et al (2003) Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 27:563-570 (Pubitemid 36514468)
58. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR (2001) Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158:527-535 (Pubitemid 32158613)
59. Kim H, Jen J, Vogelstein B, Hamilton SR (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148-156 (Pubitemid 24217493)
60. Greenson JK, Huang SC, Herron C et al (2009) Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 33:126-133
61. Jass JR, Do KA, Simms LA et al (1998) Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42:673-679 (Pubitemid 28261055)
62. Smyrk TC, Watson P, Kaul K, Lynch HT (2001) Tumorinfiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:2417-2422 (Pubitemid 32552830)
63. YearsleyM, Hampel H, Lehman A, Nakagawa H, de la Chapelle A, Frankel WL (2006) Histologic features distinguish microsatellitehigh from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Hum Pathol 37:831-838 (Pubitemid 43902942)
64. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM et al (2001) Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 48:360-366 (Pubitemid 32269564)
65. Lindor NM, Burgart LJ, Leontovich O et al (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048 (Pubitemid 34141849)
66. Muller A, Giuffre G, Edmonston TB et al (2004) Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn 6:308-315 (Pubitemid 39517398)
67. Ruszkiewicz A, Bennett G, Moore J et al (2002) Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology 34:541-547 (Pubitemid 36026729)
68. Muller W, Burgart LJ, Krause-Paulus R et al (2001) The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)-results of an international collaborative study. Fam Cancer 1:87-92 (Pubitemid 35221521)
69. Lazar V, Grandjouan S, Bognel C et al (1994) Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Hum Mol Genet 3:2257-2260
70. Halvarsson B, Lindblom A, Johansson L, Lagerstedt K, Nilbert M (2005) Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer. Mod Pathol 18:1095-1101 (Pubitemid 41224500)
71. Boland CR (2000) Molecular genetics of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci 910:50-59
72. Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257 (Pubitemid 28521189)
73. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 46:2788-2798
74. Ogino S, Shima K, Meyerhardt JA et al (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900
75. Stein A, Hiemer S, Schmoll HJ (2011) Adjuvant therapy for early colon cancer: current status. Drugs 71:2257-2275
76. Bedeir A, Krasinskas AM (2011) Molecular diagnostics of colorectal cancer. Arch Pathol Lab Med 135:578-587
77. Kang GH (2011) Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med 135:698-703
78. Kane MF, Loda M, Gaida GM et al (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811 (Pubitemid 27097998)
79. Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870-6875 (Pubitemid 28278073)
80. Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP (2005) Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 124:380-391 (Pubitemid 41232924)
81. Carr NJ, Mahajan H, Tan KL, Hawkins NJ,Ward RL (2009) Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol 62:516-518
82. Jover R, Nguyen TP, Perez-Carbonell L et al (2011) 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140:1174-1181
83. Ahuja N, Mohan AL, Li Q et al (1997) Association between CpG island methylation andmicrosatellite instability in colorectal cancer. Cancer Res 57:3370-3374 (Pubitemid 27355477)
84. Ogino S, Cantor M, Kawasaki Tet al (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised byquantitative DNA methylation analysis and prospective cohort studies. Gut 55:1000-1006 (Pubitemid 43962613)
85. Sullivan RJ, Flaherty KT (2011) BRAF inmelanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer 2011:423239
86. Kim TH, Park YJ, Lim JA et al (2011) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta-analysis. Cancer. doi:10.1002/cncr.26500
87. Tiacci E, Schiavoni G, Forconi F et al (2012) Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119:192-195
88. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934 (Pubitemid 34976022)
89. Samowitz WS, Sweeney C, Herrick J et al (2005) Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res 65:6063-6069
90. Bae JM, Kim MJ, Kim JH et al (2011) Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch 459:55-63
91. Van CE, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019
92. Di NF, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712
93. Lin JS,Webber EM, Senger CA, Holmes RS, Whitlock EP (2011) Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 1:650-662
94. Domingo E, Laiho P, Ollikainen M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41:664-668 (Pubitemid 39208606)
95. Schmiegel W, Pox C, Reinacher-Schick A et al (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 48:65-136
96. Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary nonpolyposis cancer). J Med Genet 44:353-362 (Pubitemid 46953715)
97. Teutsch SM, Bradley LA, Palomaki GE et al (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 11:3-14
98. Burt RW, Barthel JS, Dunn KB et al (2010) NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 8:8-61
99. Jarvinen HJ, Renkonen-Sinisalo L, Ktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutationpositive and mutation-negative family members. J Clin Oncol 27:4793-4797
100. Engel C, Rahner N, Schulmann K et al (2010) Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8:174-182
101. de Vos Tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45:1588-1594 (Pubitemid 35471007)
102. Parry S, Win AK, Parry B et al (2011) Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60:950-957
103. Warrier SK, Trainer AH, Lynch AC et al (2011) Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy. Dis Colon Rectum 54:1480-1487
104. Pino MS, Mino-Kenudson M, Wildemore BM et al (2009) Deficient DNA mismatch repair is common in Lynch syndromeassociated colorectal adenomas. J Mol Diagn 11:238-247
105. Rothwell PM, Wilson M, Elwin CE et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750
106. Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47-55 (Pubitemid 41002838)
107. Burn J, Gerdes AM, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081-2087
108. Dolcetti R, Viel A, Doglioni C et al (1999) High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154:1805-1813 (Pubitemid 29262862)
109. Shia J, Ellis NA, Paty PB et al (2003) Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 27:1407-1417 (Pubitemid 37315192)
110. Watson P, Lin KM, Rodriguez-Bigas MA et al (1998) Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 83:259-266 (Pubitemid 28317805)
111. Buckowitz A, Knaebel HP, Benner A et al (2005) Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 92:1746-1753 (Pubitemid 40756487)
112. Linnebacher M, Gebert J, Rudy W et al (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumorspecific antigens. Int J Cancer 93:6-11 (Pubitemid 32539494)
113. Saeterdal I, Bjorheim J, Lislerud K et al (2001) Frameshiftmutation- derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 98:13255-13260 (Pubitemid 33051349)
114. Schwitalle Y, Kloor M, Eiermann S et al (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988-997 (Pubitemid 351459601)
115. Reuschenbach M, Kloor M, Morak M et al (2010) Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer 9:173-179
116. Slupska MM, Baikalov C, Luther WM, Chiang JH, Wei YF, Miller JH (1996) Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. J Bacteriol 178:3885-3892 (Pubitemid 26227206)
117. Jones S, Emmerson P, Maynard J et al (2002) Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C->T:A mutations. Hum Mol Genet 11:2961-2967
118. Jenkins MA, Croitoru ME, Monga N et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15:312-314 (Pubitemid 43342180)
119. Sieber OM, Lipton L, Crabtree M et al (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791-799 (Pubitemid 36245755)
120. Croitoru ME, Cleary SP, Di NN et al (2004) Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96:1631-1634 (Pubitemid 39534887)
121. Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424-425
122. Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218 (Pubitemid 29144749)
123. Barrow E, Alduaij W, Robinson L et al (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74:233-242
124. Barrow E, Robinson L, Alduaij Wet al (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75:141-149
125. Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105-110 (Pubitemid 27033972)
126. Kastrinos F, Mukherjee B, Tayob N et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790-1795
127. Watson P, Vasen HF, Mecklin JP et al (2008) The risk of extracolonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444-449 (Pubitemid 351842032)